Search - tctmd.com

Displaying 361 - 380 of 467

Sort: Relevancy | Date

News Daily News

Hypertension, Underuse of Beta-Blockers Linked to Recurrent Tear in SCAD Patients

L.A. McKeown

August 24, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

Calcium Score Better Than Age for Discriminating Coronary Risk in Older Adults

Todd Neale

July 27, 2017

News Daily News

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Michael O'Riordan

July 25, 2017

News Daily News

Hormone Therapies May Have Adverse CV Effects in Transgender Adults

Ashley Lyles

July 24, 2017

News Daily News

3-D Ultrasound Quantifies Plaque Burden in Healthy Middle-Aged Cohort

Michael O'Riordan

July 11, 2017

News Conference News SCCT 2017

Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See?

Yael L. Maxwell

July 10, 2017

News Daily News

Traditional Chinese Medicine May Aid in Prevention of Cardiovascular Disease

L.A. McKeown

June 12, 2017

News Daily News

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Michael O'Riordan

June 05, 2017

News Daily News

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

L.A. McKeown

May 03, 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2017

Shelley Wood

April 28, 2017

News Conference News EAS 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

Yael L. Maxwell

April 26, 2017

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Conference News ACC 2017

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

Yael L. Maxwell

March 18, 2017

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

Meta-analysis Adds Support to More Intensive Lowering of BP in Older Patients With Hypertension

Todd Neale

January 30, 2017

Advertisement

Hypertension, Underuse of Beta-Blockers Linked to Recurrent Tear in SCAD Patients

Evolocumab Not Cost-Effective at Current List Price

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Calcium Score Better Than Age for Discriminating Coronary Risk in Older Adults

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Hormone Therapies May Have Adverse CV Effects in Transgender Adults

3-D Ultrasound Quantifies Plaque Burden in Healthy Middle-Aged Cohort

Nonobstructive Coronary Disease on Cardiac CT: Call to Action, or Wait and See?

Traditional Chinese Medicine May Aid in Prevention of Cardiovascular Disease

Debating the ARB/MI Paradox: Is It Real, or Is the Story Incomplete?

Extended DAPT May Benefit Patients With CAD and PAD, but With Caveats

TCTMD’s Top 10 Most Popular Stories for April 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Meta-analysis Adds Support to More Intensive Lowering of BP in Older Patients With Hypertension

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content